Oncolytics Biotech (ONCY) Change in Working Capital (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Change in Working Capital data on file, last reported at $1.9 million in Q3 2025.

• On a quarterly basis, Change in Working Capital fell 40.56% year-over-year to $1.9 million in Q3 2025; TTM through Sep 2025 was $442259.6, a 89.99% decrease from a year earlier, with the FY2024 full-year figure at $2.6 million, up 97.54% from the prior year.
• Change in Working Capital for Q3 2025 stood at $1.9 million, up from -$155889.9 in the prior quarter.
• Over the last five years, Change in Working Capital for ONCY reached as high as $3.2 million in Q3 2024 and fell as low as -$1.4 million in Q2 2023.
• Historically, Change in Working Capital has averaged $312988.3 across 5 years, with a median of -$24489.7 in 2024.
• Across the five-year window, Change in Working Capital soared 39497.82% in 2021 and tumbled 2330.27% in 2025, its largest moves.
• Year by year, Change in Working Capital stood at $1.3 million in 2021, then climbed by 1.47% to $1.4 million in 2022, then fell by 17.31% to $1.1 million in 2023, then sank by 161.31% to -$687215.2 in 2024, then soared by 373.65% to $1.9 million in 2025.
• Per Business Quant data, the three most recent Change in Working Capital figures were $1.9 million in Q3 2025, -$155889.9 in Q2 2025, and -$595166.7 in Q1 2025.